Tags

Type your tag names separated by a space and hit enter

The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial.
J Hum Nutr Diet. 2014 Apr; 27 Suppl 2:284-91.JH

Abstract

BACKGROUND

Attention-deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioural disorder of childhood, affecting 3-5% of school-age children. The present study investigated whether the supplementation of soy-derived phosphatidylserine (PS), a naturally occurring phospholipid, improves ADHD symptoms in children.

METHODS

Thirty six children, aged 4-14 years, who had not previously received any drug treatment related to ADHD, received placebo (n = 17) or 200 mg day(-1) PS (n = 19) for 2 months in a randomised, double-blind manner. Main outcome measures included: (i) ADHD symptoms based on DSM-IV-TR; (ii) short-term auditory memory and working memory using the Digit Span Test of the Wechsler Intelligence Scale for Children; and (iii) mental performance to visual stimuli (GO/NO GO task).

RESULTS

PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05). No significant differences were observed in other measurements and in the placebo group. PS was well-tolerated and showed no adverse effects.

CONCLUSIONS

PS significantly improved ADHD symptoms and short-term auditory memory in children. PS supplementation might be a safe and natural nutritional strategy for improving mental performance in young children suffering from ADHD.

Authors+Show Affiliations

Department of Early Childhood Education and Care, Kurashiki City College, Okayama, Japan; Daigokyou, Kyoto, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23495677

Citation

Hirayama, S, et al. "The Effect of Phosphatidylserine Administration On Memory and Symptoms of Attention-deficit Hyperactivity Disorder: a Randomised, Double-blind, Placebo-controlled Clinical Trial." Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association, vol. 27 Suppl 2, 2014, pp. 284-91.
Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet. 2014;27 Suppl 2:284-91.
Hirayama, S., Terasawa, K., Rabeler, R., Hirayama, T., Inoue, T., Tatsumi, Y., Purpura, M., & Jäger, R. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association, 27 Suppl 2, 284-91. https://doi.org/10.1111/jhn.12090
Hirayama S, et al. The Effect of Phosphatidylserine Administration On Memory and Symptoms of Attention-deficit Hyperactivity Disorder: a Randomised, Double-blind, Placebo-controlled Clinical Trial. J Hum Nutr Diet. 2014;27 Suppl 2:284-91. PubMed PMID: 23495677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. AU - Hirayama,S, AU - Terasawa,K, AU - Rabeler,R, AU - Hirayama,T, AU - Inoue,T, AU - Tatsumi,Y, AU - Purpura,M, AU - Jäger,R, Y1 - 2013/03/17/ PY - 2013/3/19/entrez PY - 2013/3/19/pubmed PY - 2014/12/15/medline KW - attention-deficit hyperactivity disorder KW - complementary and alternative KW - memory KW - phosphatidylserine KW - school children SP - 284 EP - 91 JF - Journal of human nutrition and dietetics : the official journal of the British Dietetic Association JO - J Hum Nutr Diet VL - 27 Suppl 2 N2 - BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioural disorder of childhood, affecting 3-5% of school-age children. The present study investigated whether the supplementation of soy-derived phosphatidylserine (PS), a naturally occurring phospholipid, improves ADHD symptoms in children. METHODS: Thirty six children, aged 4-14 years, who had not previously received any drug treatment related to ADHD, received placebo (n = 17) or 200 mg day(-1) PS (n = 19) for 2 months in a randomised, double-blind manner. Main outcome measures included: (i) ADHD symptoms based on DSM-IV-TR; (ii) short-term auditory memory and working memory using the Digit Span Test of the Wechsler Intelligence Scale for Children; and (iii) mental performance to visual stimuli (GO/NO GO task). RESULTS: PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05). No significant differences were observed in other measurements and in the placebo group. PS was well-tolerated and showed no adverse effects. CONCLUSIONS: PS significantly improved ADHD symptoms and short-term auditory memory in children. PS supplementation might be a safe and natural nutritional strategy for improving mental performance in young children suffering from ADHD. SN - 1365-277X UR - https://www.unboundmedicine.com/medline/citation/23495677/The_effect_of_phosphatidylserine_administration_on_memory_and_symptoms_of_attention_deficit_hyperactivity_disorder:_a_randomised_double_blind_placebo_controlled_clinical_trial_ L2 - https://doi.org/10.1111/jhn.12090 DB - PRIME DP - Unbound Medicine ER -